Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to participate in the BTIG Virtual Biotechnology Conference on July 30, 2025. The company will engage in a fireside chat at 4:40 PM ET and hold one-on-one investor meetings, focusing on their development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. A webcast of the session will be available on the Tvardi Investors' website, with a replay accessible for 60 days post-conference.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.